6:15 PM
 | 
Aug 26, 2009
 |  BC Extra  |  Company News

NICE backs Toctino, Erbitux

The U.K.'s NICE issued guidance recommending the use of Toctino alitretinoin from Basilea Pharmaceutica AG (SIX:BSLN) and Erbitux cetuximab...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >